Heart FailureNCT00930904
Model 4196 Left Ventricular (LV) Lead Chronic Performance Study
An observational study of Heart Failure, run by Medtronic at 103 sites in 8 countries.
Trial summary
The purpose of this study is to evaluate long-term performance of the 4196 LV Lead. This evaluation is based on the number of lead-related complications occurring during the study compared to the number of leads enrolled in the study. The leads will be followed for 5 years after implant. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Heart Failure
- How many people
- 1,847 participants
- Where
- 103 sitesin 8 countries
- Study dates
- Jun 2009to Apr 2017
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients implanted with a 4196 LV Lead within the past 30 days. All patients must meet Inclusion criteria and none of the Exclusion criteria.
Who may be able to join
- Patient or legally authorized representative provides written authorization and/or consent per institution and geographical requirements
- Patient has or is intended to receive an Attain Ability Model 4196 LV lead
- Patient within 30 day post implant enrollment window
Who cannot join
- Patient who is, or is expected to be inaccessible for follow-up
- Patient with exclusion criteria required by local law
- Patient is currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound results
Trial locations and contacts
103 sites in 8 countries.
103 sites in 8 countries
United States91 sites
Study site
Akron, Ohio
Study site
Albuquerque, New Mexico
Study site
Alexandria, Louisiana
Study site
Amarillo, Texas
Study site
Anchorage, Alaska
Study site
Atlanta, Georgia
Study site
Austin, Texas
Study site
Bakersfield, California
Study site
Baltimore, Maryland
Study site
Baton Rouge, Louisiana
Study site
Birmingham, Alabama
Study site
Bradenton, Florida
Study site
Browns Mills, New Jersey
Study site
Burlington, Vermont
Study site
Charleston, South Carolina
Study site
Chattanooga, Tennessee
Study site
Chula Vista, California
Study site
Cincinnati, Ohio
Study site
Clearwater, Florida
Study site
Cleveland, Ohio
Study site
Colorado Springs, Colorado
Study site
Columbia, Missouri
Study site
Columbia, South Carolina
Study site
Columbus, Georgia
Study site
Columbus, Ohio
Study site
Dallas, Texas
Study site
Denver, Colorado
Study site
Des Moines, Iowa
Study site
Downey, California
Study site
Durham, North Carolina
Study site
East Palo Alto, California
Study site
Erie, Pennsylvania
Study site
Evansville, Indiana
Study site
Fairfax, Virginia
Study site
Fargo, North Dakota
Study site
Florence, South Carolina
Study site
Fort Worth, Texas
Study site
Germantown, Tennessee
Study site
Gilbert, Arizona
Study site
Grand Blanc, Michigan
Study site
Greensboro, North Carolina
Study site
Hickory, North Carolina
Study site
Houston, Texas
Study site
Huntington, New York
Study site
Indianapolis, Indiana
Study site
Jacksonville, Florida
Study site
Kansas City, Kansas
Study site
Kansas City, Missouri
Study site
Kingsport, Tennessee
Study site
Lancaster, Pennsylvania
Study site
Lebanon, New Hampshire
Study site
Lexington, Kentucky
Study site
Little Rock, Arkansas
Study site
Long Beach, California
Study site
Louisville, Kentucky
Study site
Madison, Wisconsin
Study site
Marietta, Georgia
Study site
Marquette, Michigan
Study site
Melbourne, Florida
Study site
Milwaukee, Wisconsin
Study site
Nashville, Tennessee
Study site
Newark, Delaware
Study site
Oak Lawn, Illinois
Study site
Ocean City, New Jersey
Study site
Olympia, Washington
Study site
Parlin, New Jersey
Study site
Phoenix, Arizona
Study site
Portland, Oregon
Study site
Robbinsdale, Minnesota
Study site
Rochester, Minnesota
Study site
Saginaw, Michigan
Study site
Salinas, California
Study site
Salisbury, Maryland
Study site
San Antonio, Texas
Study site
San Bernardino, California
Study site
Sayre, Pennsylvania
Study site
Scottsdale, Arizona
Study site
Silver Spring, Maryland
Study site
Spokane, Washington
Study site
Takoma Park, Maryland
Study site
The Woodlands, Texas
Study site
Toledo, Ohio
Study site
Torrance, California
Study site
Utica, New York
Study site
Van Nuys, California
Study site
Washington D.C., District of Columbia
Study site
Wellington, Florida
Study site
West Orange, New Jersey
Study site
Winston-Salem, North Carolina
Study site
Worcester, Massachusetts
Study site
Ypsilanti, Michigan
Canada4 sites
Study site
Kingston
Study site
Ottawa, Ontario
Study site
Ste-Foy, Quebec
Study site
Toronto
About this study
Official title: Attain Ability® Model 4196 Left Ventricular Lead Chronic Performance Post Approval Study
The purpose of this study is to evaluate long-term performance of the 4196 LV Lead. This evaluation is based on the number of lead-related complications occurring during the study compared to the number of leads enrolled in the study. The leads will be followed for 5 years after implant. This study is required by FDA as a condition of approval of the Model 4196 LV Lead and is integrated within the Product Surveillance Registry (PAN Registry).
Read the detailed description
Model 4196 LV lead complication-free survivability will be summarized.
- Conditions
- Heart Failure
- Medical subject headings
- Heart Failure
What is being measured
The primary outcome is the main question the study is designed to answer.
Lead-related complication rate
Measured: 5 years
Secondary outcomes (5)
Types of lead-related events
Measured: 5 years
Percent of subjects with changes in electrode programming
Measured: 5 Years
Percent of fractures with loss of function
Measured: 5 years
Mean bipolar pacing threshold
Measured: 1 year
Mean pacing threshold and impedance via Tip and Ring unipolar pacing configurations
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Jul 2009 (estimated)
- Study startJun 2009
- Primary completionApr 2017
- Study completionApr 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Heart FailureStudies of the same condition, open and under way.
- More trials run by MedtronicThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 1,847 participants (actual)
Sponsor and investigators
- Lead sponsor
- Medtronic
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- 4196 LV Lead Chronic Performance Study Team, Study chair, Medtronic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00930904
- Sponsor's protocol ID
- 4196 Chronic Performance
- Status last verified
- Dec 2017
- First submitted
- 30 Jun 2009
- Last updated
- 27 Dec 2017
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Dec 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Attain Ability® Model 4196 Left Ventricular Lead Chronic Performance Post Approval Study
- ClinicalTrials.gov ID
- NCT00930904
- Acronym / sponsor ID
- 4196 Chronic Performance
- Conditions
- Heart Failure
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,847 participants (actual)
- Lead sponsor
- MedtronicIndustry (pharma, biotech, devices)
- Study start
- Jun 2009
- Primary completion
- Apr 2017 (actual)
- Study completion
- Apr 2017 (actual)
- First posted
- 2 Jul 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate long-term performance of the 4196 LV Lead. This evaluation is based on the number of lead-related complications occurring during the study compared to the number of leads enrolled in the study. The leads will be followed for 5 years after implant. This study is required by FDA as a condition of approval of the Model 4196 LV Lead and is integrated within the Product Surveillance Registry (PAN Registry).
Detailed description
Model 4196 LV lead complication-free survivability will be summarized.
Study design
- Observational model
- Other
- Time perspective
- Prospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients implanted with a 4196 LV Lead within the past 30 days. All patients must meet Inclusion criteria and none of the Exclusion criteria.
Key inclusion criteria (3 listed)
- Patient or legally authorized representative provides written authorization and/or consent per institution and geographical requirements
- Patient has or is intended to receive an Attain Ability Model 4196 LV lead
- Patient within 30 day post implant enrollment window
Key exclusion criteria (3 listed)
- Patient who is, or is expected to be inaccessible for follow-up
- Patient with exclusion criteria required by local law
- Patient is currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound results
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Lead-related complication rate
Time frame: 5 years
5 secondary outcomes
Types of lead-related events
Time frame: 5 years
Percent of subjects with changes in electrode programming
Time frame: 5 Years
Percent of fractures with loss of function
Time frame: 5 years
Mean bipolar pacing threshold
Time frame: 1 year
Mean pacing threshold and impedance via Tip and Ring unipolar pacing configurations
Time frame: 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Dec 2017.
Related trials for Heart Failure
Active, not recruiting
Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF)
Heart Failure, Congestive Heart Failure
Active, not recruiting
Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction
Heart Failure With Preserved Ejection Fraction, Concentric Hypertrophy
Recruiting
Vsling™ III: Clinical Evaluation of the Vsling™ Device for Ventricular Repair in Patients With Heart Failure
HFrEF - Heart Failure With Reduced Ejection Fraction
RecruitingPhase 4
Empagliflozin in Heart Failure With Reduced Ejection Fraction and End Stage Renal Disease
Heart Failure With Reduced Ejection Fraction, End Stage Renal Disease on Dialysis
Enrolling by invitationObservational study
Multi-Scale Analysis of Phenotypes in Heart Failure (MAP-HEART)
Heart Failure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
4196 LV Lead Chronic Performance Study Team study chair
Medtronic
103 sites in 8 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Heart Failure, run by Medtronic at 103 sites in 8 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Dec 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 103 sites in United States, Canada, Italy, Netherlands, Austria and 3 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Lead-related complication rate (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Dec 2017; AzTrials last refreshed its copy on 29 Oct 2026.